Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zosano Pharma (ZSAN)

Zosano Pharma (ZSAN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Zosano Pharma Announces CEO Transition

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that Steven Lo, veteran biotechnology and pharmaceutical executive, will become president and chief...

ZSAN : 2.24 (+6.67%)
Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase 100,000 shares of Zosano's common stock...

ZSAN : 2.24 (+6.67%)
Zosano Pharma to Present at the Cantor Global Healthcare Conference

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker, will present a company overview...

ZSAN : 2.24 (+6.67%)
Zosano Pharma Announces the Appointment of Dushyant Pathak, Ph.D., as Senior Vice President of Business Development

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Dushyant Pathak, Ph.D., as senior vice president of business development.

ZSAN : 2.24 (+6.67%)
Zosano Pharma Announces the Presentation of Multiple Positive Datasets from the Qtrypta(TM) Long-Term Safety Study at the Congress of the International Headache Society

- Repeated Dosing of Qtrypta Over the Course of One Year Reaffirms Qtrypta is Effective and Well-Tolerated as an Acute Treatment for Migraine -

ZSAN : 2.24 (+6.67%)
Zosano Pharma to Present at the H.C. Wainwright Annual Global Investment Conference

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker, will present a company overview...

ZSAN : 2.24 (+6.67%)
Zosano Pharma Announces Upcoming Oral and Poster Presentations at the Congress of the International Headache Society

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the company will deliver an oral presentation and two poster presentations at the 19th Congress...

ZSAN : 2.24 (+6.67%)
Jaguar Health Appoints Carol Lizak Chief Accounting Officer

SAN FRANCISCO, CA / ACCESSWIRE / August 16, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), a commercial stage pharmaceutical company focused on developing novel, sustainably derived...

ALXA : 1.0000 (+6.95%)
ZSAN : 2.24 (+6.67%)
JAGX : 0.73 (unch)
Zosano Pharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2019, as well as recent business highlights....

ZSAN : 2.24 (+6.67%)
Zosano Pharma Files IND to Initiate a Phase 2/3 Clinical Study in Cluster Headache

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug...

ZSAN : 2.24 (+6.67%)
Zosano Pharma to Host Conference Call on Second Quarter 2019 Financial Results and Provide Operational Update

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Wednesday, August 14, 2019 at 4:30 p.m. ET to discuss...

ZSAN : 2.24 (+6.67%)
Zosano Pharma Presents Migraine-ACT Scores for Qtrypta(TM) at the American Headache Society (AHS) Annual Scientific Meeting

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the presentation of Migraine-ACT scores for Qtrypta(TM) therapy used over 6-12 months. The Migraine...

ZSAN : 2.24 (+6.67%)
Zosano Pharma Announces Keynote Speech at the Pharmaceutics & Advanced Drug Delivery Systems Conference

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that Hayley Lewis, senior vice president of operations at Zosano Pharma, will be presenting a keynote...

ZSAN : 2.24 (+6.67%)
Zosano Pharma Announces Upcoming Presentation at American Headache Society Annual Meeting

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that a poster and e-poster describing Migraine-ACT scores, or measures of patient satisfaction with...

ZSAN : 2.24 (+6.67%)
Zosano Pharma Reports First Quarter 2019 Financial Results

-- Multiple catalysts, including Qtrypta NDA submission, anticipated in 2019

ZSAN : 2.24 (+6.67%)
Zosano Pharma Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 14, 2019 / Zosano Pharma Corp. (NASDAQ: ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 14, 2019 at 4:30 PM Eastern Time....

ZSAN : 2.24 (+6.67%)
Zosano Announces Full Exercise of Underwriter's Option to Purchase Additional Shares

Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has issued and sold an additional 750,000 shares of common stock, pursuant to the exercise in...

ZSAN : 2.24 (+6.67%)
Zosano Pharma to Host Conference Call on First Quarter 2019 Financial Results and Provide Operational Update

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Tuesday, May 14, 2019 at 4:30 p.m. ET to discuss...

ZSAN : 2.24 (+6.67%)
Biotech Brief: FDA Fast Tracking Innovative Breakthrough Therapies For Cancer Patients

A recent headline from a report released by Friends of Cancer Research, made the following eye-opening statement: "ONE OF THE BIGGEST TREATMENT BREAKTHROUGHS IN THE PAST FIVE YEARS WASN'T A DRUG, BUT A...

MBRX : 1.10 (-3.51%)
BPTH : 12.10 (-1.63%)
PFE : 36.68 (+0.69%)
WVE : 21.80 (+0.51%)
ZSAN : 2.24 (+6.67%)
Zosano Announces the Publication of an Analysis of Acute Treatments for Migraine in Headache: The Journal of Head and Face Pain

Zosano Pharma Corporation (NASDAQ:ZSAN) ("Zosano" or the "Company"), a clinical-stage biopharmaceutical company, today announced the peer-reviewed publication of a review and analysis of recently-completed...

ZSAN : 2.24 (+6.67%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI -1.03 , AIZ -0.24 , SBAC +1.27 , SO +0.17 , WELL -1.22
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar